bronchitis%20-%20uncomplicated%20acute
BRONCHITIS - UNCOMPLICATED ACUTE
Uncomplicated acute bronchitis is a self-limiting infection of the trachea and bronchi that usually lasts for 1 to 3 weeks. A healthy patient experiences sudden onset of cough, with or without sputum production.
It is an inflammatory response to infections of the bronchial epithelium of the large airways of the lungs that begins with mucosal injury, epithelial cell damage and release of proinflammatory mediators.
There is transient airflow obstruction and bronchial hyperresponsiveness.
Purulence can result from either bacterial or viral infection.

Bronchitis%20-%20uncomplicated%20acute Management

Follow Up

  • Though routine follow-up is not usually necessary, it provides an opportunity to check on patient’s response to therapy and compliance to lifestyle modification
  • Consider alternate diagnoses if symptoms worsen
  • Further investigation is recommended if:
    •  Symptoms recur >3x/year
    • If symptoms persist for >1 month
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 28 Sep 2020
With much remains controversial regarding the possible transmission route of SARS-CoV-2 virus, a study reveals yet another surprise worthy of caution in the hospital setting.
Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.